Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis. A Phase 2a, 2-Part, Randomized, Double-Blind, Double-Dummy Placebo-Controlled, Parallel-Group (Sponsor Open) Study to Assess Pharmacodynamics and Safety of PF-06865571 (DGAT2i) Coadministered With PF-05221304 (ACCi) in Adult Participants With Presumed Nonalcoholic Steatohepatitis (NASH).